Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.

Abstract

The recommended S-1 dose for future studies is 30 mg/m(2) twice daily, and diarrhea is the most frequent toxic effect. Additional trials of S-1 in the treatment of patients with solid tumors are warranted.